Education
About Us
Working with TipRanks
Follow Us
Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Total Valuation
Piramal Pharma Limited has a market cap or net worth of ₹276.15B. The enterprise value is ₹346.71B.
Market Cap₹276.15B
Enterprise Value₹346.71B
Share Statistics
Piramal Pharma Limited has 1.33B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.33B
Owened by Insiders
Owened by Instutions
Financial Efficiency
Piramal Pharma Limited’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Piramal Pharma Limited is ―. Piramal Pharma Limited’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Piramal Pharma Limited had revenue of ₹83.73B and earned ₹277.60M in profits. Earnings per share was ₹0.22.
Revenue₹83.73B
Gross Profit₹39.17B
Operating Income₹6.61B
Pretax Income₹2.07B
Net Income₹277.60M
EBITDA13.62B
Earnings Per Share (EPS)0.22
Cash Flow
In the last 12 months, operating cash flow was ₹7.42B and capital expenditures ₹0.00, giving a free cash flow of ₹7.42B billion.
Operating Cash Flow₹7.42B
Free Cash Flow₹7.42B
Free Cash Flow per Share₹5.59
Dividends & Yields
Piramal Pharma Limited pays an annual dividend of ₹0.11, resulting in a dividend yield of 0.05%
Dividend Per Share₹0.11
Dividend Yield0.05%
Payout Ratio31.59%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change50.23%
50-Day Moving Average213.58
200-Day Moving Average216.82
Relative Strength Index (RSI)59.04
Average Volume (3m)433.63K
Important Dates
Piramal Pharma Limited upcoming earnings date is May 21, 2025, During Market Hours.
Last Earnings DateJan 28, 2025
Next Earnings DateMay 21, 2025
Ex-Dividend DateJul 12, 2024
Financial Position
Piramal Pharma Limited as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Piramal Pharma Limited has paid ₹2.14B in taxes.
Income Tax₹2.14B
Effective Tax Rate―
Enterprise Valuation
Piramal Pharma Limited EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Piramal Pharma Limited has ₹5.02B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹5.02B billion.
Cash & Marketable Securities₹5.02B
Total Debt₹0.00
Net Cash-₹5.02B
Net Cash Per Share-₹3.78
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Piramal Pharma Limited is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast